contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magnasense-and-salignostics-successfully-complete-feasibility-study

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Magnasense operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and mainly includes drugs for the treatment of multiple sclerosis. In addition to the main business, associated ancillary services are offered. The business is run in collaboration with other pharmaceutical actors, where the largest presence is found in the Nordic region.

Magnasense

Magnasense and Salignostics are pleased to announce the successful completion of their feasibility study, initiated in September 2024. The study evaluated the transfer of an existing Salignostics...

<div class="mfn-preamble"><p><strong>Magnasense and Salignostics are pleased to announce the successful completion of their feasibility study, initiated in September 2024. The study evaluated the transfer of an existing Salignostics test onto Magnasense’s platform. The results confirmed the compatibility of Salignostics’ collection device with Magnasense’s proprietary magnetic technology.</strong></p></div><div class="mfn-body"><p>Marco Witteveen, CEO of Magnasense AB, stated:<br>“At Magnasense, we are committed to advancing diagnostic technology. Our collaboration with Salignostics has provided valuable insights into the potential of our magnetic test strip platform. We are encouraged by the study’s results and look forward to further developments.”</p><p>Dr. Guy Krief, Deputy CEO of Salignostics LTD, added:<br>“We are pleased with the study’s outcome, which highlights the synergy between our sample collection expertise and Magnasense’s magnetic technology. We look forward to exploring future opportunities together.”</p><p>The data in this feasibility study is the property of Salignostics LTD.</p></div><div class="mfn-footer mfn-contacts mfn-e503b60338ed"><p><strong class="mfn-heading-1">For additional information, please contact:</strong><br>Marco Witteveen, CEO, Magnasense AB<br>Email: <a rel="noopener" href="mailto:ir@aegirbio.com">ir@magnasense.com</a><br>The Company’s Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se</p></div><div class="mfn-footer mfn-about mfn-8c31e8f3e677"><p><strong class="mfn-heading-1">About Magnasense AB</strong><br>Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/e6d18fee-25b7-4114-89ea-648284c44374/magnasense-and-salignostics-successfully-complete-feasibility-study.pdf" class="mfn-generated mfn-primary">Magnasense and Salignostics Successfully Complete Feasibility Study</a></p></div>